{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Sanguineous vs. Crystalloid CPB Prime in Pediatric Cardiac Surgery"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 2,
        "evidence": "Forty pediatric patients were enrolled at IWK Health Centre, Halifax, Canada, between August 2020 and June 2021. Eligibility criteria included weight <30 kg and exclusion of severe hematologic or multi-organ conditions."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Sanguineous prime (n=26) vs. crystalloid prime (n=14)."
      },
      "Objective": {
        "score": 1,
        "evidence": "To identify specific inflammatory mediators in sanguineous CPB prime and their impact on the inflammatory response at CPB initiation."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Primary outcome was the concentration of inflammatory mediators at CPB initiation."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation: Not applicable as this was a post-hoc analysis of a prospective cohort study."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding: Not applicable."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Forty pediatric patients were enrolled at IWK Health Centre, Halifax, Canada, between August 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Sanguineous prime (n=26) vs. crystalloid prime (n=14)."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Sanguineous prime contained supraphysiologic concentrations of complement mediators C2, C3, C3a, C3b, and C5a. Upon CPB initiation, patients receiving sanguineous prime exhibited significantly higher levels of C2, C3, C3b, C5, and C5a (p<0.001) compared to the crystalloid group."
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT05154864."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 13,
    "max_score": 25
  },
  "model": "gpt-4o"
}